Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics will engage investors through multiple healthcare conferences and online webcasts throughout September 2026.

Rhea-AI Summary

Avalo Therapeutics (AVTX) will participate in several healthcare investor conferences in September 2026, including fireside chats, 1x1 meetings and presentations. Events include Cantor on September 10, Morgan Stanley and H.C. Wainwright on September 16, and Stifel on September 24.

Live webcasts and replays, when available, will be accessible for at least 30 days in the Investors “News / Events” section of Avalo’s website.

Argus Sep 3 session

-1.76% close to close Open Argus

Details

News Market Reaction – AVTX

On Sep 3, the day this news came out, AVTX closed 1.76% below the previous close.

Data tracked by StockTitan Argus for the Sep 3 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Cantor Global Healthcare Conference 2026

Fireside Chat
September 10, 2026, at 8:00 am ET

Morgan Stanley 24th Annual Global Healthcare Conference

1x1 meetings only
September 16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Presentation
September 16, 2026, at 8:30 am ET

Stifel 2026 Virtual Immunology and Inflammation Forum

Fireside Chat
September 24, 2026, at 9:30 am ET

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

For media and investor inquiries

Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Avalo Therapeutics (AVTX) attend in September 2026?

Avalo Therapeutics will participate in the Cantor Global Healthcare Conference 2026, Morgan Stanley 24th Annual Global Healthcare Conference, H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum.

When is Avalo Therapeutics (AVTX) presenting at the Cantor Global Healthcare Conference 2026?

Avalo Therapeutics will have a fireside chat at the Cantor Global Healthcare Conference 2026 on September 10, 2026, at 8:00 am ET.

What is Avalo Therapeutics doing at the Morgan Stanley 24th Annual Global Healthcare Conference?

At the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, Avalo Therapeutics management will participate in 1x1 investor meetings only, with no public presentation mentioned.

When will Avalo Therapeutics present at the H.C. Wainwright 28th Annual Global Investment Conference?

Avalo Therapeutics is scheduled for a presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 8:30 am ET.

What is the timing of Avalo Therapeutics’ participation in the Stifel 2026 Virtual Immunology and Inflammation Forum?

Avalo Therapeutics will join a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, at 9:30 am ET.

How can investors access Avalo Therapeutics (AVTX) conference webcasts and replays?

Live webcasts and replays, when available, can be accessed under “News / Events” in the Investors section of the Avalo Therapeutics website. Archived webcasts will be available for replay for at least 30 days.

What is Avalo Therapeutics’ main clinical focus mentioned in the conference announcement?

Avalo Therapeutics is a clinical stage biotechnology company developing therapeutics targeting the IL-1β pathway. Its lead antibody, abdakibart, is being advanced into a phase 3 registrational program in hidradenitis suppurativa, with additional IL-1β driven indications under consideration.